Clinical and biological characteristics according to the IDH mutation status
| Characteristics . | IDH wt (n = 222) . | IDH-mutated (n = 70) . | P . |
|---|---|---|---|
| Age (yr) at diagnosis median (range) | 63.1 (21.7-82.3) | 64.9 (31.2-78.2) | .23 |
| Sex, n (%) female | 116 (52) | 39 (56) | .68 |
| Hb, g/dL median (range) | 8.9 (4-15.68) | 8.2 (4.3-13.4) | .09 |
| Platelets, 109/L median (range) | 65 (1-501) | 66 (2-950) | .22 |
| WBC, 109/L median (range) | 6.3 (0.7-366) | 3.9 (0.8-385) | .96 |
| Blasts BM, % median (range) | 50 (3-95) | 61.5 (16-95) | .02 |
| Blasts PB, % median (range) | 20 (0-97) | 32 (1-97) | .15 |
| ELN2017, n (%) | |||
| Favorable | 47 (23) | 16 (27) | .33 |
| Intermediate | 69 (34) | 25 (42) | |
| Adverse | 85 (42) | 19 (32) | |
| Monosomal KT, n (%) present | 30 (14) | 2 (3.1) | .01 |
| NPM1, n (%) mutated | 51 (23) | 17 (25) | .87 |
| FLT3-ITD, n (%) present | 39 (18) | 13 (19) | .86 |
| CEBPA, n (%) mutated | 28 (14) | 8 (12) | .84 |
| ASXL1, n (%) mutated | 11 (12) | 6 (15) | .78 |
| RUNX1, n (%) mutated | 17 (20) | 1 (2.6) | .01 |
| TP53, n (%) mutated | 15 (17) | 0 (0) | .01 |
| DNMT3A, n (%) mutated | 19 (22) | 19 (48) | .01 |
| Characteristics . | IDH wt (n = 222) . | IDH-mutated (n = 70) . | P . |
|---|---|---|---|
| Age (yr) at diagnosis median (range) | 63.1 (21.7-82.3) | 64.9 (31.2-78.2) | .23 |
| Sex, n (%) female | 116 (52) | 39 (56) | .68 |
| Hb, g/dL median (range) | 8.9 (4-15.68) | 8.2 (4.3-13.4) | .09 |
| Platelets, 109/L median (range) | 65 (1-501) | 66 (2-950) | .22 |
| WBC, 109/L median (range) | 6.3 (0.7-366) | 3.9 (0.8-385) | .96 |
| Blasts BM, % median (range) | 50 (3-95) | 61.5 (16-95) | .02 |
| Blasts PB, % median (range) | 20 (0-97) | 32 (1-97) | .15 |
| ELN2017, n (%) | |||
| Favorable | 47 (23) | 16 (27) | .33 |
| Intermediate | 69 (34) | 25 (42) | |
| Adverse | 85 (42) | 19 (32) | |
| Monosomal KT, n (%) present | 30 (14) | 2 (3.1) | .01 |
| NPM1, n (%) mutated | 51 (23) | 17 (25) | .87 |
| FLT3-ITD, n (%) present | 39 (18) | 13 (19) | .86 |
| CEBPA, n (%) mutated | 28 (14) | 8 (12) | .84 |
| ASXL1, n (%) mutated | 11 (12) | 6 (15) | .78 |
| RUNX1, n (%) mutated | 17 (20) | 1 (2.6) | .01 |
| TP53, n (%) mutated | 15 (17) | 0 (0) | .01 |
| DNMT3A, n (%) mutated | 19 (22) | 19 (48) | .01 |
BM, bone marrow; ELN2017, European LeukemiaNet 2017; Hb, hemoglobin; KT, karyotype; PB, peripheral blood; WBC, white blood cells; wt, wild-type.